Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer

[1]  松田 良一郎.  LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling , 2012 .

[2]  H. Yamaue,et al.  Vaccination with peptides derived from cancer‐testis antigens in combination with CpG‐7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma , 2010, Cancer science.

[3]  Jong Hoon Park,et al.  Metastatic effect of LY-6K gene in breast cancer cells. , 2009, International journal of oncology.

[4]  Yusuke Nakamura,et al.  Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer , 2009, Cancer science.

[5]  Yusuke Nakamura,et al.  From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma , 2008, General thoracic and cardiovascular surgery.

[6]  Y. Miyagi,et al.  Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. , 2007, Cancer research.

[7]  R. Berardi,et al.  Chemotherapy for advanced gastric cancer: across the years for a standard of care , 2007, Expert opinion on pharmacotherapy.

[8]  T. Ahn,et al.  LY-6K gene: a novel molecular marker for human breast cancer. , 2006, Oncology reports.

[9]  Yusuke Nakamura,et al.  Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. , 2006, International journal of oncology.

[10]  Yusuke Nakamura,et al.  Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. , 2006, International journal of oncology.

[11]  Kazuhiro Yoshida,et al.  Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer , 2006, Clinical Cancer Research.

[12]  Y. Kodera,et al.  Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry , 2006, Gastric Cancer.

[13]  Yusuke Nakamura,et al.  Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. , 2006, International journal of oncology.

[14]  H. Iishi,et al.  Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). , 2005, Japanese journal of clinical oncology.

[15]  L. Hiller,et al.  Review of second-line chemotherapy for advanced gastric adenocarcinoma. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[17]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[18]  M. Raderer,et al.  Palliative chemotherapy for advanced gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Masahiro Toda,et al.  Identification of human tumor antigens and its implications for diagnosis and treatment of cancer , 2004, Cancer science.

[20]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[21]  G. Snow,et al.  Characterization of the human Ly‐6 antigens, the newly annotated member Ly‐6K included, as molecular markers for head‐and‐neck squamous cell carcinoma , 2003, International journal of cancer.

[22]  V. Engelhard,et al.  Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  M. Kurihara,et al.  Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer , 2000, Oncology.

[24]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[27]  M. Kurihara,et al.  Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. , 2000, Oncology.